Lucid Diligence Brief: InSilico Medicine and Lilly global partnership
Lucid Diligence Brief: InSilico Medicine and Lilly global partnership…
Lucid Diligence Brief: Fauna Bio obesity target designation with Lilly
Lucid Diligence Brief: Fauna Bio obesity target designation with Lilly…
Lucid Diligence Brief: Samsung Bioepis and G2GBIO long-acting semaglutide collaboration
Lucid Diligence Brief: Samsung Bioepis and G2GBIO long-acting semaglutide…
Lucid Diligence Brief: PRISM BioLab × Receptor.AI collaboration
Lucid Diligence Brief: PRISM BioLab × Receptor.AI collaboration Professional…
Lucid Diligence Brief: AstraZeneca and CSPC obesity and T2D collaboration
Lucid Diligence Brief: AstraZeneca and CSPC obesity and T2D collaboration…
Lucid Diligence Brief: Alveus Therapeutics $159.8 million Series A
Lucid Diligence Brief: Alveus Therapeutics $159.8 million Series A Professional…
AI in Healthcare and Digital Health Today—January 8, 2026
This roundup covers major developments across artificial intelligence,…
Lucid Diligence Brief: Halozyme × Skye Bioscience evaluating ENHANZE + nimacimab in obesity
Lucid Diligence Brief: Halozyme × Skye Bioscience evaluating ENHANZE +…
Lucid Diligence Brief: Prolynx $70m Series A for long-acting obesity candidates
Lucid Diligence Brief: Prolynx $70m Series A for long-acting obesity……
Lucid Diligence Brief: SanegeneBio and Lilly RNAi collaboration in metabolic diseases
Lucid Diligence Brief: SanegeneBio and Lilly RNAi collaboration in metabolic…
Lucid Diligence Brief: Novo Nordisk to acquire Akero Therapeutics for up to $5.2 billion
Lucid Diligence Brief: Novo Nordisk to acquire Akero Therapeutics for up to…